DLAD, EPIX, LFBG - Stocks On Our Watchlist

Oct. 16, 2009 - PRLog -- The following stocks are on the StockExplode.com watchlist:

LFBG (0%)
Left Behind Games Inc. (Public, OTC- LFBG)
Left Behind Games Inc. (LFBG) doing business as Inspired Media Entertainment, incorporated on August 27, 2002, is engaged in the development, production and sale of Christian inspirational personal computer (PC) video games based upon the Left Behind series of novels. All of the Company’s games are branded under the name of Left Behind Games. Two of the Company's primary video games are based upon the Left Behind novels and products. These entail fictional storylines focused on events at the end of the world, including the ultimate battles of good against evil. They are action oriented and suitable for an engaging series of electronic games. Its initial product was a PC game called Left Behind, eternal forces (EF). On May 20, 2008, the Company acquired the publishing and distribution rights to the PC game, Keys of the Kingdom.

DLAD (+75%)
DealerAdvance Inc. (Public, OTC- DLAD)
DealerAdvance, Inc. designs, develops, markets, sells and installs a Web-based application software and database system that manages the auto dealer-customer relationship. In January 2007, the Company launched Web DA, its Web-based version of its DealerAdvance software, for conventional desktop or laptop computers. DealerAdvance began the development of a version of Web DA for small hand-held ultra-mobile personal computers (UMPC’s) in March 2007. This product will enable any car salesperson to complete the entire sales process from virtually anywhere using any UMPC. It is developing Web DA 1.5 that incorporates additional features.

EPIX (+1,050%)
Epix Pharmaceuticals, Inc. (Public, OTC- EPIX)
EPIX Pharmaceuticals, Inc. (EPIX) is a biopharmaceutical company focused on discovering, developing and commercializing pharmaceutical products. EPIX has four internally discovered therapeutic product candidates in clinical trials. These drug candidates are PRX-00023 for depression, PRX-03140 for Alzheimer’s disease, PRX-08066 for pulmonary hypertension and PRX-07034 for cognitive impairment associated with Schizophrenia and Alzheimer’s disease. The Company's blood-pool imaging agent, Vasovist, is approved for marketing in more than 30 countries outside of the United States. The focus of EPIX's therapeutic drug discovery and development efforts is on the two classes of drug targets known as G-protein Coupled Receptors (GPCRs) and ion channels. In March 2008, the Company discontinued development of PRX-00023 due to lack of efficacy shown in a Phase 2b trial in patients with major depressive disorder.


For all companies on our watchlist, visit http://www.StockExplode.com